Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU market SARASOTA, Fla., May 12, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for locally treatable infectious diseases called the Bisphosphocin® class, today announced that it has entered into an agreement with Professional Education and Research Institute LLC (PERI) to serve as the contract research organization (CRO) for its upcoming Phase 2 clinical program of Nu-3, the Company's lead Bisphosphocin® product for the treatment of mildly infected diabetic foot ulcers (iDFU).